The Relative Strength (RS) Rating for Insulet jumped into a new percentile Wednesday, with a rise from 76 to 81.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.

Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating in the early stages of their moves.

See How IBD Helps You Make More Money In Stocks

While the stock is not near a proper buy zone right now, see if it is able to form and break out of a proper consolidation.

Insulet posted -268% earnings growth in its most recent report, while sales growth came in at 16%.

The company holds the No. 41 rank among its peers in the Medical-Products industry group. Bio Rad Labs and Staar Surgical are also among the group's highest-rated stocks.